Our medicines treat millions of people around the world, however we are conscious of the ever-evolving needs of patients and their families and constantly strive to address their unmet needs.
We are continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.
We have a rich and innovative pipeline that focuses on the needs of patients – both today and in the future. Our medicines today help people living with immunological diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, as well as neurological diseases such as epilepsy and Parkinson’s disease. More recently we have also moved into developing medicines for bone, to improve the treatment of osteoporosis and helping to create a world free of fragility fractures.
Headquartered in Brussels, Belgium, we operate in approximately 40 countries around the globe and have a major international research hub and early manufacturing centre based in the UK. Most recently, we committed to investing up to £1billion into the UK life-sciences sector over the next five years, which includes building UCB’s new R&D site in or around the Slough area.
We believe that knowledge based partnerships and expertise is essential for the rapid growth of scientific understanding, and that bringing innovative therapies to patients requires intensive cooperation. Our scientists collaborate with leading researchers from academia and industry to advance science and deliver the solutions patients need. Our open approach to innovation equips us to meet today’s biggest healthcare challenges.
UCB also actively supports the training of new talent, investing in funding studentships including work placements and mentoring for some of the country’s top student scientists. The nurturing of new PhD (Doctor of Philosophy) student scientists is an integral part of our vision to continue to develop new medicines through innovative science, and we offer support to students through access to cutting edge technology, supervision and placement opportunities.
To learn more about UCB go to www.ucb.com.
Back to: North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics